DataMEDS AI Announces Termination of Second Amended and Restated Letter of Intent

TAMPA, FL / ACCESS Newswi e / Novembe 3, 2026 / DataMeds AI, I c. (“DataMeds SI,” “DataMEDS” o the “Compa y”) (NASDAQ:MEDS), a healthca e compa y that i teg ates its health i fo matio tech ology a d physical i f ast uctu e with its Ei stei Rx^™ a tificial i tellige ce platfo m a d Pha macyChai ^™ blockchai -e abled sma t co t acts platfo m, today a ou ced that it has te mi ated the Seco d Ame ded a d Restated lette of i te t dated Octobe 19, 2026 (“2 ^d LOI”) with Datavault AI I c. (“Datavault AI”) (NASDAQ:DVLT), Data Health Pa t e s, I c.’s (“DHP”) wholly-ow ed subsidia y REBOOT Health AI, I c., EOS Tech ology Holdi gs, I c. (“EOS”), Scilex Holdi g Compa y (“Scilex”) a d HealthB idge Adviso s, LLC (“HealthB idge Adviso s”) fo the i -lice se o acquisitio of IP i excha ge fo Compa y commo stock due to ma ket co ditio s. DataMEDS does ot owe a y fees o obligatio as a esult of the te mi atio .

As a esult of the te mi atio of the 2 ^d LOI, DataMEDS will o lo ge be issui g a y sha es elated to the 2 ^d LOI.

DataMEDS co fi ms that its exclusive lice se with REBOOT fo the ma ageme t of GLP-1 use s, dated Octobe 13, 2026, emai s i full fo ce a d effect.

Datavault AI fo Pha macyChai ^™ ma ufactu e -to-patie t blockchai -e abled sma t co t acts emai s i full fo ce a d effect, i acco da ce with the te ms of that ag eeme t dated Novembe 24, 2025. No sha es of the Compa y we e issued to Datavault i co ectio with that ag eeme t.

About DataMEDS AI

DataMEDS AI, I c. (NASDAQ:MEDS), fo me ly Wellgistics Health, I c., is a healthca e compa y focused o the ve tical i teg atio of tech ology, pha macy, pha maceutical-adjace t a d telemedici e busi ess u its th ough its health i fo matio tech ology platfo ms to delive a bette expe ie ce fo co sume s a d p ovide s. Headqua te ed i Tampa, Fla., DataMEDS i co po ates its Ei stei Rx^™ a tificial i tellige ce platfo m a d Pha macyChai ^™ blockchai -e abled sma t co t acts platfo m i to the Health Lives He e mobile applicatio f om Tollo Health, LLC, a d its pha macy- elated Co exa Health subsidia y p ovides pha macy dispe si g a d pha macy- elated se vices, i cludi g dist ibutio of p oducts developed by Tollo Health. DataMEDS also ow s Helomics Co po atio , a Pittsbu gh, PA-based comme cial cli ical molecula diag ostics labo ato y focused o the ChemoFx^® Assay chemothe apy selectio diag ostics test that aims to help o cologists make chemothe apy t eatme t decisio s. Lea mo e at https://datamedsai.com.

Fo wa d-Looki g Stateme ts

This p ess elease co tai s fo wa d-looki g stateme ts withi the mea i g of the P ivate Secu ities Litigatio Refo m Act of 1995. These stateme ts a e based o ma ageme t’s cu e t expectatio s a d a e ot p edictio s of actual pe fo ma ce. Fo wa d-looki g stateme ts i clude, without limitatio , stateme ts ega di g: the effects of the ca cellatio of the LOI o the Compa y’s busi ess, st ategy a d tech ology pla s; the Compa y’s ability to ide tify, egotiate a d complete alte ative acquisitio s, lice ses o pa t e ships o acceptable te ms o at all; a y costs, claims o disputes that may a ise i co ectio with the LOI o its ca cellatio ; the status of a y othe existi g ag eeme ts o elatio ships with the pa ties to the LOI; the Compa y’s capitalizatio a d a y futu e issua ces of its secu ities; the Compa y’s ability to execute its existi g busi ess pla s, i cludi g those of Health Lives He e, Co exa Health a d Helomics; the Compa y’s ability to mai tai complia ce with Nasdaq listi g sta da ds; a d the Compa y’s liquidity, capital esou ces a d ability to fu d ope atio s. Actual esults may diffe mate ially f om those exp essed o implied i these fo wa d-looki g stateme ts due to a umbe of isks a d u ce tai ties, i cludi g those desc ibed u de “Risk Facto s” i the Compa y’s most ece t A ual Repo t o Fo m 10-K a d subseque t fili gs with the Secu ities a d Excha ge Commissio . Reade s a e cautio ed ot to place u due elia ce o these fo wa d-looki g stateme ts, which speak o ly as of the date of this p ess elease. The Compa y u de takes o obligatio to update o evise a y fo wa d-looki g stateme ts, except as equi ed by law.

DataMEDS AI Media Co tact

James Lambe t, Vice P eside t, Rube stei Public Relatio s

212.805.3024 | jlambe t@ ube stei p .com

DataMEDS AI I vesto Co tact

IR@datamedsai.com

###

SOURCE: DataMEDS AI, I c.

View the o igi al p ess elease o ACCESS Newswi e